What is the long-term trend for BioCryst Pharmaceuticals's occupancy and related charges?

Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's occupancy and related charges has grown at a 6.5% compound annual growth rate (CAGR), from $1.66M to $2.01M.

BioCryst Pharmaceuticals BCRX Occupancy and Related Charges

Occupancy and Related Charges at other companies

Ionis PharmaceuticalsIONS

$6.5M+12.1%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseExpense.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's occupancy and related charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's occupancy and related charges?: BioCryst Pharmaceuticals (BCRX) reported occupancy and related charges of $706K in Q1 2026.
How has BioCryst Pharmaceuticals's occupancy and related charges changed year-over-year?: BioCryst Pharmaceuticals's occupancy and related charges increased by 29.8% year-over-year, from $544K to $706K.
What is the long-term trend for BioCryst Pharmaceuticals's occupancy and related charges?: Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's occupancy and related charges has grown at a 6.5% compound annual growth rate (CAGR), from $1.66M to $2.01M.